Skip to main content

Table 2 Relative risks for PSA relapse-free survival according to the studied variables

From: Outcomes of high-dose intensity-modulated radiotherapy alone with 1 cm planning target volume posterior margin for localized prostate cancer

Variable RR 95% CI Total PSA relapse % p
Stage       0.058
 T1a/T1b/T1c 1.00   73 5 6.8  
 T2a/T2b/T2c 2.91 1.04 – 8.17 62 13 21.0  
 T3a/T3b 6.02 0.67 – 54.22 5 1 20.0  
Gleason score       0.774
 ≤ 6 1.00   53 6 11.3  
 7 1.08 0.37 – 3.12 56 8 14.3  
 8 – 10 1.50 0.46 – 4.94 31 5 16.1  
PSA       0.493
 < 10 1.00   106 13 12.3  
 10 – 19.9 1.74 0.61 – 4.97 28 5 17.9  
 ≥ 20 2.07 0.27 – 16.21 6 1 16.7  
NCCN Risk Group       0.331
 Low 1.00   36 3 8.3  
 Intermediate 1.61 0.43 – 5.94 64 9 14.1  
 High 2.62 0.67 – 10.16 40 7 17.5  
Age (years)       0.324
 < 60 1.00   21 2 9.5  
 ≥ 60 e < 75 2.15 0.48 – 9.49 86 15 17.4  
 ≥ 75 0.89 0.12 – 6.53 33 2 6.1  
Total    140 19 13.6  
  1. Abbreviations: NCCN = National Comprehensive Cancer Network; PSA = prostate-specific antigen; RR = relative risk; CI = confidence interval.